ATEZOLIZUMAB

Search structure
Trade Names:
Synonyms:
Status: Approved (2016)
Entry Type: Antibody
Molecule Category: UNKNOWN
ATC: L01XC32
UNII: 52CMI0WC3Y

Pharmacology

Action Mechanism of Action Reference
INHIBITOR Programmed cell death 1 ligand 1 inhibitor FDA

Indications

Mesh Heading Maximum Phase Mesh ID Reference
Neoplasms 4 D009369 ClinicalTrials
Breast Neoplasms 4 D001943 ClinicalTrials
Breast Neoplasms 4 D001943 ClinicalTrials
Breast Neoplasms 4 D001943 ClinicalTrials
Lung Neoplasms 4 D008175 ClinicalTrials
Peritoneal Neoplasms 3 D010534 ClinicalTrials
Prostatic Neoplasms 3 D011471 ClinicalTrials
Small Cell Lung Carcinoma 3 D055752 ClinicalTrials
Melanoma 3 D008545 ClinicalTrials
Mesothelioma 3 D008654 ClinicalTrials
Urinary Bladder Neoplasms 3 D001749 ClinicalTrials
Uterine Cervical Neoplasms 3 D002583 ClinicalTrials
Fallopian Tube Neoplasms 3 D005185 ClinicalTrials
Ovarian Neoplasms 3 D010051 ClinicalTrials
Uterine Cervical Neoplasms 3 D002583 ClinicalTrials
Esophageal Neoplasms 3 D004938 ClinicalTrials
Ovarian Neoplasms 3 D010051 ClinicalTrials
Esophageal Neoplasms 3 D004938 ClinicalTrials
Esophageal Neoplasms 3 D004938 ClinicalTrials
Urogenital Neoplasms 3 D014565 ClinicalTrials
Triple Negative Breast Neoplasms 3 D064726 ClinicalTrials
Endometrial Neoplasms 3 D016889 ClinicalTrials
Carcinoma, Hepatocellular 3 D006528 ClinicalTrials
Mesothelioma 3 D008654 ClinicalTrials
Ovarian Neoplasms 3 D010051 ClinicalTrials
Carcinoma, Squamous Cell 3 D002294 ClinicalTrials
Colorectal Neoplasms 3 D015179 ClinicalTrials
Melanoma 3 D008545 ClinicalTrials
Carcinoma, Non-Small-Cell Lung 3 D002289 ClinicalTrials
Melanoma 3 D008545 ClinicalTrials
Prostatic Neoplasms 3 D011471 ClinicalTrials
Carcinoma, Renal Cell 3 D002292 ClinicalTrials
Urinary Bladder Neoplasms 3 D001749 ClinicalTrials
Carcinoma 2 D002277 ClinicalTrials
Leukemia, Lymphocytic, Chronic, B-Cell 2 D015451 ClinicalTrials
Lymphoma, Follicular 2 D008224 ClinicalTrials
Hodgkin Disease 2 D006689 ClinicalTrials
Lymphoma, Large B-Cell, Diffuse 2 D016403 ClinicalTrials
Stomach Neoplasms 2 D013274 ClinicalTrials
Glioblastoma 2 D005909 ClinicalTrials
Lymphoma 2 D008223 ClinicalTrials
Head and Neck Neoplasms 2 D006258 ClinicalTrials
Sarcoma, Alveolar Soft Part 2 D018234 ClinicalTrials
Rectal Neoplasms 2 D012004 ClinicalTrials
Sezary Syndrome 2 D012751 ClinicalTrials
Mycosis Fungoides 2 D009182 ClinicalTrials
Sarcoma 2 D012509 ClinicalTrials
Carcinoma, Pancreatic Ductal 2 D021441 ClinicalTrials
Pancreatic Neoplasms 2 D010190 ClinicalTrials
Head and Neck Neoplasms 2 D006258 ClinicalTrials
Cholangiocarcinoma 2 D018281 ClinicalTrials
Neoplasm Metastasis 2 D009362 ClinicalTrials
Retroviridae Infections 2 D012192 ClinicalTrials
Anus Neoplasms 2 D001005 ClinicalTrials
Kidney Neoplasms 2 D007680 ClinicalTrials
Prostatic Neoplasms, Castration-Resistant 2 D064129 ClinicalTrials
Lymphoma, Follicular 2 D008224 ClinicalTrials
Biliary Tract Neoplasms 2 D001661 ClinicalTrials
Thyroid Neoplasms 2 D013964 ClinicalTrials
Cholangiocarcinoma 2 D018281 ClinicalTrials
Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1 D015464 ClinicalTrials
Multiple Myeloma 1 D009101 ClinicalTrials
Liver Neoplasms 1 D008113 ClinicalTrials
Myelodysplastic Syndromes 1 D009190 ClinicalTrials
Glioma 1 D005910 ClinicalTrials
Leukemia, Myeloid, Acute 1 D015470 ClinicalTrials
Gliosarcoma 1 D018316 ClinicalTrials
Lymphoma, Non-Hodgkin 1 D008228 ClinicalTrials
Skin Neoplasms 1 D012878 ClinicalTrials
Hematologic Neoplasms 1 D019337 ClinicalTrials

Adverse Reactions

SOC By Demographic Distribution
System Organ Classification (SOC)
Relative Frequency (%)
General disorders and administration site conditions
12.3
Respiratory, thoracic and mediastinal disorders
10.25
Gastrointestinal disorders
7.81
Nervous system disorders
6.47
Investigations
6.14
Infections and infestations
6.1
Vascular disorders
5.94
Cardiac disorders
5.68
Blood and lymphatic system disorders
5.6
Metabolism and nutrition disorders
5.56
Injury, poisoning and procedural complications
4.39
Immune system disorders
3.81
Musculoskeletal and connective tissue disorders
3.43
Renal and urinary disorders
3.41
Skin and subcutaneous tissue disorders
3.01
Hepatobiliary disorders
2.85
Endocrine disorders
2.24

Cross References

Resources Reference
CAS NUMBER 1380723-44-3
ChEMBL CHEMBL3707227
FDA SRS 52CMI0WC3Y
Guide to Pharmacology 7990
CONTENTS